ArticleBioengineering (Basel, Switzerland)2026
A Tissue-Compliant Shape-Memory Composite Membrane for Cardiac Occluders.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ventricular septal defect (VSD) occluders commonly rely on permanent nitinol frameworks, which may contribute to long-term mechanical mismatch and late complications. Here, we developed a tissue-compliant composite membrane by embedding a 3D-printed poly(vinyl alcohol) (PVA) grid within a shape-memory poly(glycerol dodecanedioate) (PGD) matrix. Grid spacing was varied from 0.1 to 0.5 mm to tune reinforcement density. FTIR indicated that PVA was incorporated mainly through physical interlocking rather than new covalent bonding. The composite preserved near-body-temperature shape recovery. In water at 37 °C, PVA reinforcement increased tensile modulus and fracture strength, although swelling also increased. Finite-element analysis and benchtop occlusion testing consistently showed lower deformation, less strain localization, and smaller bulge height for PGD-PVA than for PGD alone. In vitro assays showed low cytotoxicity, low hemolysis, and prolonged plasma recalcification time. A 12-week pilot degradation study showed that the faster mass loss observed in initial samples was mainly caused by exposed PVA cut edges; after switching to a fully encapsulated design, static mass loss became similar across groups, and dynamic PBS agitation produced about 10% mass loss at 12 weeks. These results support PGD-PVA as a reinforced membrane strategy for polymeric occluders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.